Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;74(8):939-44.
doi: 10.1007/s40265-014-0229-1.

Tofogliflozin: first global approval

Raewyn M Poole  1 , Jennifer E Prossler
Affiliations

Tofogliflozin: first global approval

Raewyn M Poole et al. Drugs. 2014 Jun.

Abstract

Tofogliflozin (Apleway(®), Deberza(®) [Japan]), an orally active small molecule sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by Chugai Pharmaceutical for the treatment of type 2 diabetes mellitus (T2DM), and a marketing authorization application was filed in Japan in 2013 by licensees Sanofi K.K. and Kowa. Tofogliflozin has received its first global approval for this indication in Japan as either monotherapy or in combination with other antihyperglcaemic agents. This article summarizes the milestones in the development of tofogliflozin leading to this first approval for the treatment of T2DM.

PubMed Disclaimer

References

    1. J Pharmacol Exp Ther. 2013 Apr;345(1):52-61 - PubMed
    1. Diabetes Metab Res Rev. 2013 Jul;29(5):347-56 - PubMed
    1. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23 - PubMed
    1. Lancet Diabetes Endocrinol. 2013 Oct;1(2):140-51 - PubMed
    1. Diabetes. 2012 Sep;61(9):2199-204 - PubMed

MeSH terms

Substances

LinkOut - more resources